Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05071612 · ClinicalTrials.gov registry record · Phase 2
Parallel Arm Trial of AD109 and AD504 In Patients With OSA
A Phase 2 study, sponsored by Apnimed.
- Completed
- Registry status
- Phase 2
- Development phase
- 294
- Enrollment target
NCT05071612 is a Phase 2 study that has completed, run by Apnimed. The registered enrollment target is 294 participants.
The verdict
NCT05071612, a Phase 2 study, has completed, sponsored by Apnimed.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 294 participants
- Enrollment target
Study Summary
This is a phase 2 randomized double-blind placebo-controlled parallel-arm dose finding study to compare fixed dose combinations of AD109 and AD504 to atomoxetine or placebo in Obstructive Sleep Apnea.
Interventions
- DRUG Placebo
- DRUG AD109
- DRUG Atomoxetine Hydrochloride
- DRUG AD504
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2021-11-29 |
| Est. Completion | 2022-08-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05071612
The ClinicalTrials.gov registry entry for NCT05071612 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apnimed, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05071612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05071612 about?
NCT05071612 is a clinical study titled "Parallel Arm Trial of AD109 and AD504 In Patients With OSA". This is a phase 2 randomized double-blind placebo-controlled parallel-arm dose finding study to compare fixed dose combinations of AD109 and AD504 to atomoxetine or placebo in Obstructive Sleep Apnea.
What is the current status of trial NCT05071612?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 294 participants. The study started on 2021-11-29. Estimated completion is 2022-08-03.
What interventions are being tested in trial NCT05071612?
The interventions under investigation include: Placebo (DRUG), AD109 (DRUG), Atomoxetine Hydrochloride (DRUG), AD504 (DRUG).
Who is sponsoring clinical trial NCT05071612?
This trial is sponsored by Apnimed, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.